2-acetamidobenzohydroxamic acid | 119721-54-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-acetamidobenzohydroxamic acid
• 英文别名: Benzamide, 2-(acetylamino)-N-hydroxy-；2-acetamido-N-hydroxybenzamide
• CAS: 119721-54-9
• 化学式: C₉H₁₀N₂O₃
• 分子量: 194.19
• InChiKey: HRJYGTNYWSUPAW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  78.4
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• Hydroxamic acid and its derivatives as inhibitors of melanocyte tyrosinase for topical skin lighteners
  申请人：Integriderm, Inc.

  公开号：US20030199558A1

  公开（公告）日：2003-10-23

  Methods, compounds, and formulations are provided to reduce pigmentation in mammalian skin, comprising hydroxamic acid and its derivatives, and especially benzohydroxamic acid and its derivatives. The compounds preferably inhibit pigment synthesis in melanocytes through inhibition of melanocyte tyrosinase. The methods can be used for lightening skin, and for treating uneven skin complexions, which result from hyperpigmentation-related medical conditions such as melasma, age spots, freckles, ochronosis, and lentigo. The compounds can be used medically or cosmetically, and preferably as topical formulations.

  提供了一种用于减少哺乳动物皮肤色素沉着的方法、化合物和配方，包括羟羧酸及其衍生物，尤其是苯甲羟羧酸及其衍生物。这些化合物通过抑制黑素细胞酪氨酸酶的活性，从而抑制黑色素合成。这些方法可用于美白皮肤，治疗因色素沉着相关医疗状况（如雀斑、老年斑、晒斑、黑变病和雀斑）而导致的不均匀肤色。这些化合物可在医学上或美容上使用，最好作为局部制剂。
• HYDROXAMIC ACID AND ITS DERIVATIVES AS INHIBITORS OF MELANOCYTE TYROSINASE FOR TOPICAL SKIN LIGHTENERS
  申请人：Integriderm, Inc.

  公开号：EP1461010A2

  公开（公告）日：2004-09-29
• [EN] HYDROXAMIC ACID AND ITS DERIVATIVES AS INHIBITORS OF MELANOCYTE TYROSINASE FOR TOPICAL SKIN LIGHTENERS<br/>[FR] ACIDE HYDROXAMIQUE ET SES DERIVES COMME INHIBITEURS DE LA MELANOCYTE TYROSINASE POUR ECLAIRCISSANTS TOPIQUES DE LA PEAU
  申请人：INTEGRIDERM INC

  公开号：WO2003057184A2

  公开（公告）日：2003-07-17

  Methods, compounds, and formulations are provided to reduce pigmentation in mammalian skin, comprising hydroxamic acid and its derivatives, and especially benzohydroxamic acid and its derivatives. The compounds preferably inhibit pigment synthesis in melanocytes through inhibition of melanocyte tyrosinase. The methods can be used for lightening skin, and for treating uneven skin complexions, which result from hyperpigmentation-related medical conditions such as melasma, age spots, freckles, ochronosis, and lentigo. The compounds can be used medically or cosmetically, and preferably as topical formulations.